Astagraf XL

How Hard Is It to Find Astagraf XL in Stock?

As of 2026, Astagraf XL is not on an active FDA or ASHP drug shortage list. Astellas confirms availability of all three strengths (0.5 mg, 1 mg, 5 mg). However, Astagraf XL has a findability score of 55 out of 100 due to its brand-only status, specialty pharmacy distribution, and the absence of a commercially available generic.

Many standard retail pharmacies do not consistently stock Astagraf XL, particularly in all three strengths. Patients are most likely to find it reliably at specialty pharmacies focused on transplant medications. Localized stocking gaps at retail chains are common. The strict non-interchangeability requirement means pharmacies cannot substitute another tacrolimus product without physician supervision.

If your pharmacy is out of stock, medfinder can call pharmacies near you to find which ones have Astagraf XL in your strength in stock, saving you hours of phone calls. Always refill 7-10 days before running out and consider using a transplant specialty pharmacy for more reliable access.

Who Can Prescribe Astagraf XL?

Astagraf XL is not a controlled substance, but its FDA prescribing information states it must be used under the supervision of a physician experienced in immunosuppressive therapy and organ transplant management. It is not appropriate for prescription by general practitioners without transplant expertise.

• Transplant nephrologists -- primary managers of post-kidney-transplant immunosuppression
• Transplant surgeons -- particularly in the immediate post-transplant period
• Transplant clinical pharmacists -- often manage dosing adjustments under physician oversight
• Trained transplant nurse practitioners and physician assistants -- within established transplant programs
• Pediatric transplant physicians -- for pediatric kidney transplant patients who can swallow capsules

Telehealth follow-up is available for stable kidney transplant recipients already established on Astagraf XL therapy, but initiation and acute management require in-person care within a transplant center setting.

Is Astagraf XL a Controlled Substance?

No. Astagraf XL (tacrolimus extended-release capsules) is not a controlled substance and is not scheduled under the DEA Controlled Substances Act. It does not have abuse potential and is not subject to the prescription refill restrictions that apply to Schedule II-V controlled substances.

However, Astagraf XL is a prescription-only medication that requires a physician experienced in immunosuppressive therapy. It cannot be prescribed by general practitioners without transplant expertise. The prescribing physician must monitor tacrolimus blood levels and kidney function regularly throughout treatment.

Common Side Effects of Astagraf XL

Astagraf XL carries an FDA Boxed Warning about increased risks of serious infections and malignancies, and increased mortality in female liver transplant patients. Common side effects include:

• Nephrotoxicity (kidney damage) -- very common, requires regular monitoring
• Hypertension (high blood pressure)
• New-onset diabetes after transplant (NODAT) -- higher risk in African-American and Hispanic patients
• Tremor and neurotoxicity
• Diarrhea, nausea, stomach upset
• Headache and insomnia
• Hyperkalemia (high potassium levels)
• Anemia

Serious Side Effects of Astagraf XL

• Serious infections (bacterial, viral including BK virus, CMV, PML/JC virus; and fungal/protozoal)
• Lymphoma and other malignancies (especially skin cancer)
• QT prolongation and Torsades de pointes (serious heart arrhythmia)
• Posterior reversible encephalopathy syndrome (PRES) -- neurological emergency
• Pure red cell aplasia

Final Thoughts on Astagraf XL

Astagraf XL (tacrolimus extended-release capsules) is a cornerstone medication for kidney transplant recipients, providing the convenience of once-daily dosing while delivering effective immunosuppression. FDA-approved in 2013 and available in 73 countries, it has become a standard option in post-transplant care alongside twice-daily tacrolimus IR formulations.

Finding Astagraf XL can be challenging at standard retail pharmacies due to its brand-only, specialty-distributed status. Using a transplant specialty pharmacy and refilling early are the most reliable strategies. For commercially insured patients, the Astellas Cares copay card can reduce out-of-pocket costs to as little as $0 per fill with up to $3,000 in annual savings.

If you're having trouble finding Astagraf XL in stock, medfinder can call pharmacies near you to find which ones have your prescription ready to fill. Never skip doses or switch formulations without your transplant team's guidance -- consistent tacrolimus blood levels are essential to protecting your transplanted kidney.